NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis

被引：0
|
作者：
O'Reilly, Eileen [1 ]
Li, Jia [2 ]
DerSarkissian, Maral [3 ]
Chang, Rose [4 ]
Cheng, Mu [4 ]
Yu, Louise [4 ]
Rane, Deepali [2 ]
Zhang, Li [2 ]
Xiao, Zhimin [2 ]
Benzaghou, Fawzi [5 ]
Duh, Mei Sheng [4 ]
Chen, Huanyu [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Ipsen Corp, Paris, France
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Anal Grp Inc, Boston, MA USA
[5] IPSEN, Paris, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
442
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [31] Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients
    Ningzhen Fu
    Yu Jiang
    Kai Qin
    Hao Chen
    Xiaxing Deng
    Baiyong Shen
    BMC Cancer, 21
  • [32] Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients
    Fu, Ningzhen
    Jiang, Yu
    Qin, Kai
    Chen, Hao
    Deng, Xiaxing
    Shen, Baiyong
    BMC CANCER, 2021, 21 (01)
  • [33] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    George, Ben
    Kent, Matthew
    Surinach, Andy
    Lamarre, Neil
    Cockrum, Paul
    Chudnovsky, Aleksander
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Real-world treatment patterns and total cost of care in Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX
    Hirsch, Jared
    Cockrum, Paul
    Tomicki, Samantha
    Dieguez, Gabriela
    Bhatt, Prachi
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L)
    Dennen, Syvart
    Silver, Michelle
    Cockrum, Paul
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
    Julien Taieb
    Thomas Seufferlein
    Michele Reni
    Daniel H. Palmer
    John A. Bridgewater
    Antonio Cubillo
    Gerald W. Prager
    Alice Vermeire
    Fabienne Hédouin-Biville
    Zhaoyang Teng
    Teresa Macarulla
    BMC Cancer, 23
  • [38] Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
    Taieb, Julien
    Seufferlein, Thomas
    Reni, Michele
    Palmer, Daniel H.
    Bridgewater, John A.
    Cubillo, Antonio
    Prager, Gerald W.
    Vermeire, Alice
    Hedouin-Biville, Fabienne
    Teng, Zhaoyang
    Macarulla, Teresa
    BMC CANCER, 2023, 23 (01)
  • [39] IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
    Kim, G. P.
    Surinach, A.
    Corvino, F. A.
    Cockrum, P.
    VALUE IN HEALTH, 2019, 22 : S58 - S58
  • [40] Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX
    Dieguez, Gabriela
    Tomicki, Samantha
    Cockrum, Paul
    Hirsch, Jared
    Bhatt, Prachi
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345